LEADER 00657nam0-22002411i-450- 001 990002735480403321 035 $a000273548 035 $aFED01000273548 035 $a(Aleph)000273548FED01 035 $a000273548 100 $a20000920d1980----km-y0itay50------ba 101 0 $aENG 200 1 $aControllo di gestione$eAspetti tecnico cont abili.$fdi BANDETTINI A 210 $aPadova$cCedam$d1980. 700 1$aBandettini,$bAntonio$0249876 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990002735480403321 952 $a9-11-33$bS.I.$fECA 959 $aECA 996 $aControllo di gestione$9424475 997 $aUNINA DB $aING01 LEADER 01019nam0-22002891i-450- 001 990002040820403321 005 20060515162358.0 035 $a000204082 035 $aFED01000204082 035 $a(Aleph)000204082FED01 035 $a000204082 100 $a20030910d1952----km-y0itay50------ba 101 0 $ager 200 1 $aAlte und neue Pepsis-Arten, Hymenoptera-Sphecoidea, Pompilidae, olim Psammocharidae auct.$emit einem Anhang, Der Stachelapparat der spinnenfangenden Raubwespen$fHermann Haupt 210 $aLeipzig$cJohann Ambrosius Barth$d1952 215 $ap.311-414$d27 cm 225 1 $aNova Acta Leopoldina$v109 610 0 $aImenotteri$aSphecoidea$aPompilidae 676 $a595.79 700 1$aHaupt,$bHermann$0360564 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990002040820403321 952 $a61 V D.9/128$b3374 (11/12/70)$fDAGEN 959 $aDAGEN 996 $aAlte und neue Pepsis-Arten, Hymenoptera-Sphecoidea, Pompilidae, olim Psammocharidae auct$9407682 997 $aUNINA LEADER 04705nam 2200565Ia 450 001 9910737299803321 005 20200520144314.0 010 $a1-4614-6464-1 024 7 $a10.1007/978-1-4614-6464-8 035 $a(CKB)2560000000102936 035 $a(EBL)1317801 035 $a(SSID)ssj0000894451 035 $a(PQKBManifestationID)11475623 035 $a(PQKBTitleCode)TC0000894451 035 $a(PQKBWorkID)10854373 035 $a(PQKB)11066622 035 $a(DE-He213)978-1-4614-6464-8 035 $a(MiAaPQ)EBC1317801 035 $a(PPN)170487628 035 $a(EXLCZ)992560000000102936 100 $a20130522d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aPharmacoresistance in epilepsy $efrom genes and molecules to promising therapies /$fLuisa Rocha, Esper A. Cavalheiro, editors 205 $a1st ed. 2013. 210 $aNew York $cSpringer$dc2013 215 $a1 online resource (332 p.) 300 $aDescription based upon print version of record. 311 $a1-4899-9504-8 311 $a1-4614-6463-3 320 $aIncludes bibliographical references and index. 327 $aPharmacoresistance and Epilepsy -- Genes involved in pharmacoresistant epilepsy -- Pathological oscillations in the pharmacoresistant epileptic brain -- Molecular mechanisms of pharmacoresistant epilepsy -- Modifications in the seizures susceptibility by excitotoxic neuronal damage and its possible relationship with the pharmacoresistance -- Intracellular pathways associated with neuronal survival and death in epilepsy -- The role of JNK pathway in the process of excitotoxicity induced by epilepsy and neurodegeneration -- Proteomics-based strategy to identify biomarkers and pharmacological targets in temporal lobe epilepsy -- Abnormalities of GABA system and human pharmacoresistant epilepsy -- Pharmacoresistant epilepsy and immune system -- Contribution of the antiepileptic drug administration regime in the development and/or establishment of pharmacoresistant epilepsy -- Experimental models to study pharmacoresistance in epilepsy -- Resistance to epileptogenesis in the Neotropical rodent Proechimys -- On the development of new antiepileptic drugs for the treatment of pharmacoresistant epilepsy ? Different approaches to different hypothesis -- Modulating P-glycoprotein regulation as a therapeutic strategy for pharmacoresistant epilepsy -- Vagus Nerve Stimulation for Intractable Seizures -- The role of neuromodulation in the treatment of refractory epilepsy -- Transcranial magnetic stimulation and refractory partial epilepsy -- Effects of transcranial focal electrical stimulation via concentric ring electrodes on seizure activity -- Physical exercise as a strategy to reduce seizure susceptibility. 330 $aAlthough more than 10 new antiepileptic drugs have been developed in the past decade, epilepsy remains resistant to drug therapy in about one-third of patients, many of whom struggle with the disease their entire lives. Managing these patients is a challenge and requires a structured multidisciplinary approach. The book includes chapters on all issues related to pharmacoresistance in epilepsy, and describes recent developments in the pathogenesis and treatment of this disorder. It addresses abnormalities in inhibitory mechanisms, epilepsy-related changes to the immune system, development of pharmacoresistance caused by chronic exposure to antiepileptic drugs, and novel therapeutic strategies for preventing or slowing down the progression of the disease. Clinicians and basic scientists alike will find up-to-date information on the development of pharmacoresistance, as well as reviews of mechanisms associated with epilepsy that may help them consider novel strategies for preventing the development of pharmacoresistance in the first place. The book also features information on new therapeutic strategies for control of epilepsy, such as transcutaneous electrical stimulation and virtual screening of new antiepileptic drugs. Pharmacoresistance in Epilepsy: From Genes and Molecules to Promising Therapies is useful to anyone working in the field, whether they?re studying epilepsy in the lab or treating it in a doctor?s office. 606 $aEpilepsy 606 $aDrug resistance 615 0$aEpilepsy. 615 0$aDrug resistance. 676 $a616.853061 701 $aRocha$b Luisa$01752518 701 $aCavalheiro$b Esper A$01752519 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910737299803321 996 $aPharmacoresistance in epilepsy$94187842 997 $aUNINA